CONNECTING THE DOTS
OF MARKET ACCESS.

Medical technology companies trust the JD Lymon Group (JDL), to develop creative, street-smart solutions to overcome barriers to market access, de-risk potential problems before they arise, and provide the guidance to smooth out the path to reimbursement and market success.

Founded by three highly respected healthcare strategists with decades of combined experience, JDL creates strategic, integrated, multidisciplinary pathways that help medical technology companies understand their unique value proposition and optimize their market potential.

At every stage of development – from an idea on a napkin to your company’s next acquisition – JDL serves as a collaborative partner dedicated to accelerating market access for groundbreaking medical and biopharmaceutical technologies.

WHO WE ARE

Jolayne Devers, President and Partner - MBA, CPC, CPC-H, CPC-P at JD Lymon Group

JOLAYNE DEVERSPresident and Partner - MBA, CPC, CPC-H, CPC-P

For more than 35 years, Jolayne (Jo) has worked in the health care industry in a variety of sectors, including a world-leading medical device company, a large commercial payer, and a provider organization. As a consultant and Certified Professional Coder, she has used her broad experience to build a unique expertise in medical device and biopharmaceutical optimization strategies for product reimbursement and market access, and has successfully established numerous Medicare payment mechanisms in addition to obtaining CPT, ICD-10 and HCPCS codes for emerging technologies. Jolayne also currently provides CPT, RUC and strategic consulting to the American Society of General Surgery to guide them through the CPT code development process and on the political and economic changes that affect general surgeons and the quality care they provide for their patients.

Jolayne earned a Bachelor of Science degree from the University of St. Catherine and an MBA from the University of St. Thomas. She has taught national programs for HMP’s Wound Clinic Business on reimbursement and was an adjunct faculty member in St. Thomas University’s Medical Device Reimbursement.

Mark Domyahn, Partner - MBA at JD Lymon Group

MARK DOMYAHNPartner - MBA

With more than 25 years of experience in the health care industry, Mark provides expertise to clients in medical technology, provider reimbursement and health economics. Prior to joining JDL, Mark founded Pursuance Consulting, a reimbursement and health economics consulting practice developing successful reimbursement strategies and implementation plans for medical device, ranging from start-ups to Fortune 500 companies. He has also served in market access leadership positions at Medtronic, Restore Medical, CardioMEMS and Zimmer, where he formulated and executed reimbursement and health economic strategies for multiple therapy areas, including heart failure, cardiology, neuromodulation, orthopedics, and sleep disorders. Over his career, Mark has successfully established incremental Medicare payments for numerous new technologies across a wide variety of therapeutic areas, resulting in higher long-term payment for these technologies.

Mark holds an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Science in Accounting from Minnesota State University Moorhead. He is a frequent presenter regarding reimbursement and health economic strategy and implications across the United States.

Carla Monacelli, Partner at JD Lymon Group

CARLA MONACELLIPartner

Carla is an entrepreneur at heart and has worked in the field of reimbursement, healthcare policy, and government relations more than 35 years. She has played a significant role with numerous medical device companies, including serving as the Global Vice President of Government Affairs and Market Access (GAMA) for Nevro, and Vice President of GAMA for LivaNova, AqueSys and Torax Medical.

Carla has developed and implemented strategic reimbursement plans for both biotechnology and medical device companies. She has been involved with the launch or reimbursement strategies for hundreds of technologies, including multiple companies that have had successful exits. Her strength is working with clients to integrate healthcare policy and reimbursement solutions into the overall business plan, examining the trade-offs and timing of various strategies, ultimately resulting in removing reimbursement as a barrier to market adoption.

Carla holds a Bachelor’s degree in Political Science from the University of Minnesota. She is a national speaker on healthcare policy and reimbursement issues.

WHY THE JD LYMON GROUP

Every day, medical device and biopharmaceutical companies are developing new treatments to cure diseases, ease the pain of those suffering, and allow more people to live longer, happier, and higher quality lives.

In today’s complex healthcare market, there are many hurdles that companies must overcome. One of the greatest of these is securing appropriate reimbursement. Without it, medical device and biopharmaceutical companies face a significant uphill battle getting their products to market, including obtaining funding to realize their dreams.

At JDL, we understand this reality. As a trusted advisor to medical device and biopharmaceutical companies, we listen to your ideas and develop innovative strategies to effectively and efficiently navigate companies through the complex and ever-shifting healthcare landscape. There’s a lot of pressure on life science companies to secure reimbursement for their medical innovations. We thrive on it. Combining experts in policy, clinical trial reimbursement planning, coding and payment applications, development and execution of thorough market access commercialization strategies, we deliver custom solutions based on the unique needs of our clients through a comprehensive combination of experience and expertise.

A WINNING COMBINATION:
WE BRING TOGETHER SEASONED EXPERTS WITH PROVEN SUCCESS IN HEALTH POLICY, COVERAGE, CODING AND PAYMENT TO OPTIMIZE COMMERCIALIZATION STRATEGIES.

JDL knows every nook and cranny of this business. We understand how to look around the corners. We anticipate when significant change is coming and prepare our clients accordingly. And because of this, we have built a sterling reputation for quality and an ability to get results.

WE CARE ABOUT OUR CLIENTS. WE WANT TO BE ON THE SAME WINNING TEAM – WE WANT TO SEE OUR CLIENTS SUCCEED.

At the center of everything we do is collaboration. JDL works closely with its clients to truly understand their business and the demands placed on those businesses by investors, regulators, the medical community and ultimately, the patients. Based on decades of experience, we provide straightforward, practical strategies designed to meet the real-life demands of this industry. We’ve built a trustworthy reputation by providing practical and actionable market access strategies that help companies overcome the hurdles they face to accelerate their growth.

FROM AN IDEA ON A NAPKIN TO YOUR NEXT ACQUISITION, WE PROVIDE THE STRATEGY AND SOLUTIONS TO MAKE THINGS HAPPEN.

OUR EXPERTISE

We work with a wide range of clients, from start-ups that are still in clinical trials to Fortune 500 companies and everything in between. We are proud that some of the most successful entrepreneurs and leaders in the health care industry have repeatedly trusted us to be their partners in bringing game changing technologies to the market.

The partners of JDL have collectively supported the product development and launch efforts of hundreds of products in the last 30+ years. Our experience includes accelerating market access for the following:

MEDICAL DEVICES
SOFTWARE AS A SERVICE
DURABLE MEDICAL EQUIPMENT
BIOLOGICS AND ORPHAN THERAPIES

We accelerate market access with strategies that address the complex interrelationships among health policy, reimbursement and commercial execution.

JD Lymon Group office building

JD LYMON GROUP

750 MAIN STREET, SUITE 206
MENDOTA HEIGHTS, MN 55118